Novel anticancer drug curaxin CBL0137 impairs DNA methylation by eukaryotic DNA methyltransferase Dnmt3a
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (16), 127296
- https://doi.org/10.1016/j.bmcl.2020.127296
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Structure and Function of Mammalian DNA MethyltransferasesChemBioChem, 2010
- Dimeric bisbenzimidazoles inhibit the DNA methylation catalyzed by the murine Dnmt3a catalytic domainJournal of Enzyme Inhibition and Medicinal Chemistry, 2010
- New Hopes from Old Drugs: Revisiting DNA-Binding Small Molecules as Anticancer AgentsFuture Oncology, 2009
- RETRACTED: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its DegradationCancer Research, 2009
- Impact of 7,8-Dihydro-8-oxoguanine on Methylation of the CpG Site by Dnmt3aBiochemistry, 2009
- Sp transcription factor family and its role in cancerEuropean Journal Of Cancer, 2005
- ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISMAnnual Review of Pharmacology and Toxicology, 2005
- DNA methylation and human diseaseNature Reviews Genetics, 2005
- Doxorubicin Inhibits DNMT1, Resulting in Conditional ApoptosisPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- DNA methylation patterns and epigenetic memoryGenes & Development, 2002